The estimated Net Worth of Pharmaceuticals, Inc. Alnylam is at least $24 Million dollars as of 23 February 2016. Pharmaceuticals Alnylam owns over 1,000,000 units of Regulus Therapeutics Inc stock worth over $7,540,943 and over the last 12 years Pharmaceuticals sold RGLS stock worth over $16,421,935.
Pharmaceuticals has made over 10 trades of the Regulus Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Pharmaceuticals sold 1,000,000 units of RGLS stock worth $7,180,000 on 23 February 2016.
The largest trade Pharmaceuticals's ever made was selling 1,000,000 units of Regulus Therapeutics Inc stock on 23 February 2016 worth over $7,180,000. On average, Pharmaceuticals trades about 198,267 units every 49 days since 2012. As of 23 February 2016 Pharmaceuticals still owns at least 4,896,716 units of Regulus Therapeutics Inc stock.
You can see the complete history of Pharmaceuticals Alnylam stock trades at the bottom of the page.
Pharmaceuticals's mailing address filed with the SEC is 300 THIRD STREET, 3RD FLOOR, , CAMBRIDGE, MA, 02142.
Over the last 12 years, insiders at Regulus Therapeutics Inc have traded over $78,282,075 worth of Regulus Therapeutics Inc stock and bought 65,288,007 units worth $66,275,578 . The most active insiders traders include Forest Baskett, Scott D Sandell, and Anthony A. Jr. Florence. On average, Regulus Therapeutics Inc executives and independent directors trade stock every 34 days with the average trade being worth of $890,488. The most recent stock trade was executed by Kathryn J Collier on 25 July 2024, trading 4,000 units of RGLS stock currently worth $7,280.
regulus therapeutics inc. (nasdaq:rgls) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting micrornas. regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microrna therapeutics pipeline complemented by a maturing micromarkerssm biomarkers platform and a rich intellectual property estate to retain its leadership in the microrna field. regulus is developing rg-101, a galnac-conjugated anti-mir targeting microrna-122 for the treatment of chronic hepatitis c virus infection, and rg-012, an anti-mir targeting microrna-21 for the treatment of alport syndrome, a life-threatening kidney disease driven by genetic mutations with no approved therapy. in addition, rg-125, a galnac-conjugated anti-mir targeting microrna-103/107 for the treatment of nash in patients with type 2 diabetes/pre-diabetes, has entered phase i clinical development through its strategic alliance with astrazeneca. reg
Regulus Therapeutics Inc executives and other stock owners filed with the SEC include: